Posters

Aspiration as a treatment for recurrent stromal iris cyst

Poster Details

First Author: G.Athanasopoulos GREECE

Co Author(s): S. Diafas   D. Giannoulis   R. Bartzoulianou   D. Moschou   D. Kapantais   F. Topouzis     

Abstract Details

Purpose:

To present a rare case of recurrent primary iris stromal cyst OS in an 8 year old male, which occupied the majority of the anterior chamber and was managed twice with aspiration.

Setting:

A’ Ophthalmology Department, Aristotle University of Thessaloniki, AHEPA Hospital

Methods:

This is a case report. To the best of our knowledge, iris cysts are rare and very challenging, as far as diagnosis and treatment are concerned. Therefore, a diagnostic paracentesis - aspiration under general anesthesia was initially planned, following a complete ophthalmologic and ultrasonographic assessment. Ten months later, a recurrence was noted, which led to a second aspiration procedure, along with hydrodissection of the cyst wall from endothelium.

Results:

Aspiration of iris cyst resulted to decrease of cyst volume and dimensions, increase of its internal clarity and improvement of visual acuity. Second aspiration surgery had similar results which are sustained during follow up visits. Cytology test of first aspiration material had no diagnostic value, whereas it was indicative of benign stromal cyst after the second surgery. Following both procedures, a severe anterior chamber inflammation was noted, accompanied by transient elevation of intraocular pressure. These conditions were managed successfully. The child has been consistently monitored through monthly follow-up visits and is currently under topical non steroidal anti-inflammatory treatment.

Conclusions:

A minimally invasive approach, such as needle drainage of the cyst, which had been initially planned for diagnostic purpose, finally turned out to be therapeutic, which, combined with thorough examination and continuous follow-up, can lead to efficient management of a primary iris stromal cyst and its secondary complications.

Financial Disclosure:

None